<DOC>
	<DOCNO>NCT00525525</DOCNO>
	<brief_summary>This phase II study Bevacizumab plus Temodar Tarceva patient non-progressive glioblastoma gliosarcoma . Patients must stable disease immediately follow standard course up-front radiotherapy Temodar . All patient receive Bevacizumab , Temodar Tarceva . A total 60 patient enrol . Our hypothesis combination Bevacizumab plus Temodar Tarceva increase survival see historical control newly diagnose , non-progressive glioblastoma gliosarcoma follow radiotherapy plus Temodar use Temodar alone .</brief_summary>
	<brief_title>Study Bevacizumab Plus Temodar Tarceva Patients With Glioblastoma Gliosarcoma</brief_title>
	<detailed_description>Patients newly diagnose glioblastoma gliosarcoma treat standard care radiation temozolomide , plus addition Bevacizumab Tarceva . The dose temozolomide , Bevacizumab radiation patient . Tarceva dose base upon use enzyme induce anti-epileptic agent . Tarceva give daily ; Bevacizumab give every 2 week ; radiation 6 week , temozolomide give daily radiotherapy adjuvant setting , give 5-day schedule every 28 day . Patients follow progression survival . The measure response MR scanning every 2 month . Dose adjustment base upon specific toxicity agent question differs agent ( Bevacizumab , temozolomide , Tarceva ) . Patients randomize , assign arm base use anti-epileptic agent .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Patients histologically proven , nonprogressive glioblastoma multiforme ( GBM ) gliosarcoma ( GS ) stable disease immediately follow XRT + TMZ . All patient receive Bevacizumab plus Tarceva TMZ . Biopsy resection must perform prior RT + TMZ . No chemotherapy allow prior start RT + TMZ , include Gliadel Wafers . Patients start RT + TMZ prior registration study entry eligible long progressive disease start Bevacizumab + TMZ Tarceva within 4 week completion RT + TMZ . Patients MUST treat least 54 Gy radiotherapy ( 60 Gy recommend ) MUST receive Temodar concurrently radiotherapy eligibility study . Patients may may measurable evaluable disease contrast MR imaging . A postradiotherapy MRI scan must document stable disease . Patients must &gt; 18 year old life expectancy &gt; 12 week . Patients must Karnofsky performance status ≥ 70 . Patients must adequate bone marrow function ( WBC &gt; 3,000/µl , ANC &gt; 1,500/mm3 , platelet count &gt; 100,000/mm3 , hemoglobin &gt; 10 mg/dl ) , adequate liver function ( SGOT bilirubin &lt; 1.5 time ULN ) , adequate renal function ( creatinine &lt; 1.5 mg/dL ) start therapy . These test must perform within 14 day prior initial treatment . Patients must evidence recent hemorrhage baseline MRI brain , follow exception : presence hemosiderin , resolve hemorrhage change relate surgery , presence punctuate hemorrhage tumor . Patients must significant medical illness investigator 's opinion adequately control appropriate therapy , would compromise patient 's ability tolerate therapy disease obscure toxicity dangerously alter drug metabolism . Patients must proteinuria screen demonstrate either Urine protein : creatinine ( UPC ) ratio ³ 1.0 screening OR Urine dipstick proteinuria ≥ 2+ ( patient discover ≥ 2+ proteinuria dipstick urinalysis baseline undergo 24 hour urine collection must demonstrate ≤ 1g protein 24 hour eligible ) . Patients must inadequately control hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 mmHg ) antihypertensive medication . Patients must prior history hypertensive crisis hypertensive encephalopathy . Patients must New York Heart Association Grade II great congestive heart failure ( see Appendix E ) . Patients must history myocardial infarction unstable angina within 12 month prior study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Glioblastoma</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Temodar</keyword>
</DOC>